Citations

Clear

635 citation(s) found for "Carter, R".

Terminology Change for Small Low-Risk Papillary Thyroid Cancer As a Response to Overtreatment: Results from Three Australian Community Juries
Shih, Patti , Nickel, Brooke , Degeling, Chris , Brito, Juan P. , McLeod, Donald S.A. , McCaffery, Kirsten , Carter, Stacy M. , Brito, Juan P , Thomas, Rae

Mayo Clinic

Thyroid® | November 26, 2020 | Volume: 31 | Issue: 7 | Pages: 1067-1075

10.1089/thy.2020.0694 | PMID 33238815 Get It

Background: The majority of small papillary thyroid cancers (sPTCs) are treated surgically, rather than by active surveillance. Patient and clinician preference for surgery may be partially driven by the use of cancer terminology. Some experts propose that changing terminology would better communicate the indolent nature of sPTCs and improve uptake of active surveillance. Others argue that terminology that includes “cancer” correctly reflects the biological nature of these tumors. The views of informed lay publics can provide value-based perspectives on complex issues and guide policy discussions. Methods: We recruited 40 people for three community juries, held in Sydney, Wodonga, and Cairns, Australia. Participants were of diverse backgrounds and ages, recruited through random digit dialing and a topic-blinded social media strategy. Juries were informed about thyroid cancer, overdiagnosis, and overtreatment, and heard arguments for and against terminology change before deliberation. The deliberative process in Jury 1 led to a refinement of jury charge, the updated version that was then used in Juries 2 and 3. Results: Jury 1 favored no terminology change, and Juries 2 and 3 were divided on the topic. Key reasons for opposing terminology change included a strong desire to retain terminology that aligns with the pathological definition of cancer, and to avoid even a minimal risk of harm that could arise if patients became complacent in follow-up. Key reasons to support terminology change included a desire to reduce psychological distress, stigma, and discrimination associated with a cancer diagnosis, and an argument that terminology change may be a more effective trigger for health system reform compared with other options. The juries unanimously recommended community education and health system reforms to reduce harms of overtreatment, and expressed an expectation that clinicians and researchers reach agreement on clinical guidelines to promote better uptake of active surveillance. Conclusions: The conceptual tension between a pathological and an outcome-based understanding of cancer was apparent in deliberation. This highlights an ongoing challenge for those advocating changing disease terminology. Regardless of action on terminology, jurors shared a strong expectation that practical changes would be made to respond to the harms of overtreatment.
Scientific integrity: what a journal can and cannot do
Lüscher, Thomas F. , Fox, Kim , Hamm, Christian W. , Carter, Rickey E. , Taddei, Stefano , Simoons, Maarten L. , Crea, Filippo , Crea, Filippo , Carter, Rickey E , Taddei, Stefano , Crea, Filippo , Lüscher, Thomas F

Mayo Clinic

European Heart Journal | November 18, 2020 | Volume: 41 | Issue: 48 | Pages: 4552-4555

10.1093/eurheartj/ehaa963 | PMID 33354718 Get It

Frequent CTNNB1 p.S45 Mutations and Aggressive Clinical Behavior in Neuromuscular Choristoma-Associated Fibromatosis
Carter, Jodi M. , Maldonado, Andrés A. , Howe, B. Matthew, Okuno, Scott H. , Spinner, Robert J. , Carter, Jodi , Maldonado, Andres A.

Mayo Clinic

Neurosurgery | November 13, 2020 | Volume: 88 | Issue: 4 | Pages: 804-811

10.1093/neuros/nyaa534 | PMID 33442732 Get It

Abstract BACKGROUND Neuromuscular choristoma (NMC) is a peripheral nerve malformation frequently associated with a fibromatosis (NMC-DTF) that mimics sporadic desmoid-type fibromatosis (DTF). Sporadic DTF is often managed conservatively but its clinical behavior varies. CTNNB1 mutational subtypes in sporadic DTF have prognostic value. We have previously identified CTNNB1 mutations in NMC, and 3 paired NMC-DTF but the clinical behavior of NMC-DTF is poorly understood. OBJECTIVE To evaluate patients with NMC-DTF to determine (1) CTNNB1 mutational subtypes in NMC-DTF, and (2) associated clinical behavior and response to treatment. METHODS Retrospective review of clinical, imaging, and pathologic features of patients with NMC and NMC-DTF, and molecular testing for CTNNB1 mutations. RESULTS Among 7 patients with NMC of the sciatic nerve (median age: 18 yr), NMC-DTF (mean size 10.7 cm) developed shortly following NMC biopsy (N = 5) or spontaneously (N = 2): 6 NMC-DTF had CTNNB1 p.S45X mutations and 1 NMC-DTF had a p.T41A mutation. All patients with CTNNB1 -p.S45-mutated NMC-DTF developed local progression after wide local excision or active surveillance, including one distal metachronous NMC-DTF. No patient had spontaneous disease stabilization. Following adjuvant radiation or systemic therapy, disease stabilization was achieved in 4 (of 6) patients. One patient progressed on sorafenib treatment. CONCLUSION NMC-DTF frequently contain CTNNB1 p.S45 mutations, behave aggressively, and require adjuvant therapies for disease stabilization. We now use imaging alone to diagnose NMC, and routinely surveille the NMC-affected nerve segment to identify early NMC-DTF. In contrast to sporadic DTF, earlier adoption of systemic therapeutic strategies may be required for optimal disease management of NMC-DTF.
Abstract 17219: Non-Invasive, Blood-Free Point of Care Test to Rapidly Exclude Myocardial Injury: The AI ECG
Sandoval, Yader , Jaffe, Allan S. , Friedman, Paul A. , Attia, Zachi I. , Carter, Rickey E. , Kapa, Suraj , López-Jiménez, Francisco , Noseworthy, Peter A. , Jaffe, Allan S.

Mayo Clinic

Circulation | November 12, 2020 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.17219 Get It

Background: Myocardial injury results in release of cardiac troponin (cTn) into the bloodstream, readily detected by high-sensitivity cTn (hs-cTn) assays. A noninvasive, rapid, home-based test to exclude acute myocardial injury at the time of the test and for the next 7 hours would help manage patients with suspected myocardial infarction. Since myocyte injury is associated with ECG changes, we hypothesized an artificial intelligence ECG (AI-ECG) could identify absence of injury. Objective: To train and test an AI-ECG convolutional neural network (CNN) to identify patients using a single ECG who are suspected of myocardial infarction who are low risk, with hs-cTn levels below the 99 th percentile at test time and for the subsequent 7 hours. Methods: A CNN tuned to identify the absence of a hs-cTnT (5 th Gen cTnT Roche Diagnostics) >15ng/L for men and >10ng/L for women was developed. All ECGs were recorded within one hour of the hs-cTnT assay. We used 73,012 ECGs and hs-cTnT pairs from 47,542 unique patients to train the network, 9031 ECGs from 5,811 patients for internal validation to optimize hyperparameters, and 11,904 ECGs with 21,191 hs-cTnT measurements up to 7 hours after the ECG, from 11,904 different patients as a holdout test set. Results: The mean age was 63.9±17.5 years, and 30,348 of the 59,446 patients (51%) were male. 5,852 patients (49.1%) had no elevation of hs-cTnT and 6,052 (50.9%) had an hs-cTnT above the 99 th percentile at baseline or within 7 hours of the test. Of the 11,904 patients in the test set, using a sensitive threshold, the 12 lead AI ECG identified 1037 patients (8.7%) likely to have a low risk for subsequent hs-cTnT increases > 99 th % (AUC 0.86), and the single lead ECG identified 685 patients. Of the 1037 low risk pts, 59 had an hs-cTnT > 99 th percentile within 7 hours. The mean maximum hs-cTnT among the 59 low-risk patients was 53 ng/L ± 92 vs 184 ng/L ± 1474 in the others. None of these low risk patients died within 14 days of the test. Conclusion: Use of the AI ECG to identify patients without cardiac injury at the time of the test and for 7 subsequent hours is feasible. This may permit rapid, point of care, home-based, bloodless, painless testing to exclude cardiac injury, facilitating care and management of patients with suspected ischemia.
Abstract 17152: Artificial Intelligence ECG for the Detection of Cardiac Injury as Confirmed by High Sensitivity Cardiac Troponin T-Concentrations
Sandoval, Yader , Jaffe, Allan S. , Friedman, Paul A. , Attia, Zachi I. , Carter, Rickey E. , Kapa, Suraj , López-Jiménez, Francisco , Noseworthy, Peter A. , Jaffe, Allan S.

Mayo Clinic

Circulation | November 12, 2020 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.17152 Get It

Background: High-sensitivity cardiac troponin (hs-cTn) assays quantify cTn in patients at very low concentrations. Myocyte injury due to ischemia or other pathologies cause blood levels to increase, which is prognostic. A noninvasive, rapid, broadly available, home-based test to detect hs-cTn increases would facilitate risk-stratification. Since myocyte injury is associated with ECG changes, we hypothesized an artificial intelligence ECG (AI-ECG) could non-invasively predict current or impending hs-cTnT elevations. Objective: To develop an AI-ECG convolutional neural network (CNN) to detect an abnormal hs-cTnT (5 th Gen cTnT, Roche Diagnostics) concentration using a 12-lead ECG, and a single lead ECG (lead I), which would enable smartphone, home-based detection. Methods: We developed single lead and 12-lead ECG CNNs to detect a) hs-cTnT concentrations that were at or above the 6ng/L limit that can be reported b) above the 99 th percentile upper limits of >15ng/L for men and >10ng/L for women. All ECGs were recorded within one hour of the hs-cTnT measurements. We used 73,012 ECG and hs-cTnT pairs from 47,542 unique patients to train the network, 9031 ECGs from 5,811 patients for internal validation to optimize hyperparameters, and 18,276 ECG and hs-cTnT pairs from 11,904 different patients as a holdout test set to determine the area under the receiver-operator curve (AUC). Results: The mean age was 63.9±17.5 years, and 30,348 of the 59,446 patients (51%) were male. Of the 91,288 hs-cTnT pairs 73,271 (80.2%) were above 6ng/L and 50,799 (55.6%) are above the 99 th percentile. In the test set, the AUC for the detection of a hs-cTnT level higher than 6ng/L was 0.88 using the 12 lead ECG and 0.834 with the single lead. For the detection of hs-cTnT level above of 99 th percentile, the 12 lead ECG AUC was 0.853 and the single lead was 0.806. Conclusion: The AI-ECG permits detection of levels of hs-cTnT consistent with myocardial injury. This may allow a home-based, non-invasive test that would be massively scalable and could further enhance rapid-risk stratification and patient triage with potentially significant cost reductions and enable novel triage strategies at sites without hs-cTn assays.
Healthcare Worker With Large Vessel Acute Ischemic Stroke Likely Related to Mild SARS-CoV-2 Infection
Castillo, Carlos , Lamotte, Guillaume , Mehta, Amit , Sonti, Rajiv , Maria, Gianluca Di, Ruiz, Daniel Carnevali , Kumar, Princy , Stemer, Andrew B., Denny, Mary Carter , Castillo-Pinto, Carlos , Denny, M Carter , Mehta, Amit , Lamotte, Guillaume

Mayo Clinic

The Neurohospitalist | November 10, 2020 | Volume: 12 | Issue: 1 | Pages: 48-56

10.1177/1941874420966845 | PMID 34950386 Get It

We report the case of a healthcare worker who presented with a large vessel acute ischemic stroke in setting of a mild SARS-CoV-2 infection and provide a review of the emerging literature on COVID-related stroke. A 43-year-old female presented with right-sided hemiparesis, aphasia and dysarthria. She had a nonproductive of cough for 1 week without fever, fatigue or dyspnea. A CT Head, CT angiography and CT perfusion imaging revealed a M1 segment occlusion of the left middle cerebral artery requiring transfer from a primary to a comprehensive stroke center. A nasopharyngeal swab confirmed SARS-CoV-2 infection prior to arrival at the accepting center. During the thrombectomy a 3 cm thrombus was removed. Thrombus was also evident in the 8 French short sheath during closure device placement so a hypercoagulable state was suspected. Stroke work-up revealed a glycosylated hemoglobin of 8.7%, elevation of inflammatory markers and an indeterminate level of lupus anticoagulant IgM. On discharge home, she had near complete neurological recovery. This case highlights suspected mechanisms of hypercoagulability in SARS-CoV-2 infection and the importance of optimizing stroke care systems during the COVID-19 pandemic.
Tissue-resident CD8 + T cells drive age-associated chronic lung sequelae after viral pneumonia
Goplen, Nick P., Wu, Yue , Son, Young Min , Li, Chaofan , Wang, Zheng , Cheon, In Su , Jiang, Li , Chini, Eduardo N. , Johnson, Aaron J. , Vassallo, Robert , Goplen, Nicholas P , Ayasoufi, Katayoun , Johnson, Aaron J. , Vassallo, Robert , Zhang, Nu , Sun, Jie , Li, Chaofan , Zhu, Bibo , Limper, Andrew H. , Sun, Jie

Mayo Clinic

Science Immunology | November 6, 2020 | Volume: 5 | Issue: 53 | Pages: No page available

10.1126/sciimmunol.abc4557 | PMID 33158975 Get It

Age-associated T RM cell malfunction supports chronic lung inflammation and tissue fibrosis after respiratory viral infection.
HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization
Geiersbach, Katherine B. , Sill, Daniel R, Meyer, Reid G., Yuhas, Jason, Sukov, William R. , Mounajjed, Taofic, Carter, Jodi M. , Jenkins, Robert B. , Chen, Beiyun, Yuhas, Jason A, Carter, Jodi , Geiersbach, Katherine

Mayo Clinic

Archives of Pathology & Laboratory Medicine | October 28, 2020 | Volume: 145 | Issue: 7 | Pages: 883-886

10.5858/arpa.2020-0273-oa | PMID 33112955 Get It

Context.— Guidelines for HER2 testing in breast cancer have changed over time, from the US Food and Drug Administration guideline to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines published in 2007, 2013, and 2018. Objective.— To investigate the change in assignment of HER2 status in breast cancers with equivocal (2+) immunohistochemistry (IHC) results by fluorescence in situ hybridization (FISH) following implementation of the ASCO/CAP 2018 guideline. Design.— The study included 3556 invasive breast cancers that were HER2 equivocal (2+) by IHC and were submitted to our FISH laboratory after July 2018. Reflex testing (with repeat IHC staining) was performed on certain categories of FISH results known as groups 2, 3, and 4. Concomitant review of IHC and FISH was performed on these reflex cases per 2018 guideline recommendations. The FISH data were analyzed to compare US Food and Drug Administration and ASCO/CAP 2007, 2013, and 2018 interpretations. Results.— Of 3548 invasive breast cancers with complete data available, the percentage agreement for FISH according to different guidelines was highest for ASCO/CAP 2018 versus US Food and Drug Administration (96.5%), followed by ASCO/CAP 2018 versus 2007 (93.8%), and lowest with ASCO/CAP 2018 versus 2013 (83.7%). Per the 2018 guideline, reflex IHC testing was performed on 633 breast cancers (17.8%); the majority of reflex testing results were negative (541 of 633; 85.5%). The overall distribution of HER2 FISH results (per the 2018 guideline) was 88.5% negative and 11.5% positive. Conclusions.— By eliminating the equivocal FISH category, the 2018 ASCO/CAP guideline significantly reduced the HER2 FISH–positive rate in tumors with equivocal (2+) IHC results.
P01.02 HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer
Asmann, YW, Ren, Yingxue , Wickland, DP, Sarangi, Vivekananda , Tian, Shiye, Block, MS, Sherman, ME, Knutson, KL, Carter, Jodi M. , Mansfield, Aaron S. , Lin, Yi

Mayo Clinic

E-Poster Presentations | October 1, 2020 | Volume: No volume available | Issue: No issue available | Pages: A8-A8

10.1136/jitc-2020-itoc7.15 Get It